Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Prevention |
RCV000244003 | SCV000308373 | likely benign | not specified | criteria provided, single submitter | clinical testing | ||
Labcorp Genetics |
RCV000889015 | SCV001032674 | likely benign | not provided | 2024-01-14 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000889015 | SCV001793943 | likely benign | not provided | 2020-03-04 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002487124 | SCV002802850 | likely benign | Epiphyseal dysplasia, multiple, 2; Stickler syndrome, type 5 | 2021-11-16 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000244003 | SCV004241613 | likely benign | not specified | 2023-12-22 | criteria provided, single submitter | clinical testing | Variant summary: COL9A2 c.1871-8G>T alters a non-conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. Consensus agreement among computation tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 4.6e-05 in 240756 control chromosomes. To our knowledge, no occurrence of c.1871-8G>T in individuals affected with Epiphyseal dysplasia, multiple, 2 and no experimental evidence demonstrating its impact on protein function have been reported. Three submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as likely benign. Based on the evidence outlined above, the variant was classified as likely benign. |